These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 1673637

  • 1. An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbB-2 (HER-2/neu) oncogene.
    Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE.
    Cancer Res; 1991 May 15; 51(10):2593-8. PubMed ID: 1673637
    [Abstract] [Full Text] [Related]

  • 2. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 3. Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
    De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O.
    Cancer Res; 1992 Apr 01; 52(7):1916-23. PubMed ID: 1348016
    [Abstract] [Full Text] [Related]

  • 4. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 5. Tumorigenicity in athymic mice of the human colon carcinoma cell line SW1116 expressing the tumor-associated antigenic determinant CA 19-9.
    Klug TL, Salzman S, Quinn A, Melincoff GA, Sedmak DD, Tubbs RR, Zurawski VR.
    Cancer Res; 1984 Nov 06; 44(11):5212-8. PubMed ID: 6207914
    [Abstract] [Full Text] [Related]

  • 6. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage.
    Pupa SM, Ménard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI.
    Oncogene; 1993 Nov 06; 8(11):2917-23. PubMed ID: 8105438
    [Abstract] [Full Text] [Related]

  • 7. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.
    Cancer Res; 1993 Jan 01; 53(1):94-100. PubMed ID: 8093231
    [Abstract] [Full Text] [Related]

  • 8. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R.
    Cancer Res; 1993 Oct 15; 53(20):4960-70. PubMed ID: 8104689
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC.
    Clin Cancer Res; 1999 Feb 15; 5(2):343-53. PubMed ID: 10037184
    [Abstract] [Full Text] [Related]

  • 10. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines.
    Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK.
    Cancer Res; 1991 Sep 01; 51(17):4575-80. PubMed ID: 1678683
    [Abstract] [Full Text] [Related]

  • 11. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 12. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
    Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA.
    J Nucl Med; 1997 Dec 29; 38(12):1944-50. PubMed ID: 9430475
    [Abstract] [Full Text] [Related]

  • 13. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ.
    Cancer Res; 1999 Mar 15; 59(6):1347-55. PubMed ID: 10096569
    [Abstract] [Full Text] [Related]

  • 14. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T, Luoh SW.
    Carcinogenesis; 2008 Mar 15; 29(3):473-9. PubMed ID: 17916906
    [Abstract] [Full Text] [Related]

  • 15. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.
    Yu D, Wang SS, Dulski KM, Tsai CM, Nicolson GL, Hung MC.
    Cancer Res; 1994 Jun 15; 54(12):3260-6. PubMed ID: 7911396
    [Abstract] [Full Text] [Related]

  • 16. The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3.
    Alper O, Yamaguchi K, Hitomi J, Honda S, Matsushima T, Abe K.
    Cell Growth Differ; 1990 Dec 15; 1(12):591-9. PubMed ID: 1981143
    [Abstract] [Full Text] [Related]

  • 17. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
    Meenakshi A, Kumar RS, Kumar NS.
    Hum Antibodies; 2001 Dec 15; 10(3-4):101-7. PubMed ID: 11847421
    [Abstract] [Full Text] [Related]

  • 18. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.
    Oncogene; 1994 Jul 15; 9(7):1829-38. PubMed ID: 7911565
    [Abstract] [Full Text] [Related]

  • 19. Oncogenic potential of erbB-2 in human mammary epithelial cells.
    Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP, Aaronson SA.
    Oncogene; 1991 Jul 15; 6(7):1189-94. PubMed ID: 1713661
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M, Yao J, Yu D.
    Cancer Res; 1997 Mar 15; 57(6):1199-205. PubMed ID: 9067293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.